Overview Financials News + Filings Key Docs Charts Ownership Insiders |
MINDBODY, Inc. (MB)
|
Add to portfolio |
|
|
Price: |
$36.46
| | Metrics |
OS: |
47.9
|
M
| |
-14
|
% ROE
|
Market cap: |
$1.75
|
B
| |
-17
|
% ROIC
|
Net cash:
|
$75.7
|
M
| |
$1.58
|
per share
|
EV:
|
$1.67
|
B
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($21.9)
|
M
| |
|
|
EBIT
|
($37.8)
|
M
| |
|
|
EPS |
($0.82)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
Date Filed | Type | Description |
11/01/2019 |
GN
| FINAL DEADLINE ALERT - MINDBODY, Inc. (MB) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Lead Plaintiff Deadline: November 4, 2019 |
10/23/2019 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MINDBODY, Inc. - MB |
10/20/2019 |
GN
| ROSEN, A LEADING LAW FIRM, Reminds MINDBODY, Inc. Investors of Important November 4th Deadline in Securities Class Action – MB |
09/27/2019 |
GN
| ROSEN, A TOP RANKED LAW FIRM, Reminds MINDBODY, Inc. Investors of Important Deadline in Securities Class Action – MB |
09/27/2019 |
GN
| Meredith Corporation (MDP), MINDBODY, Inc. (MB) & - Cadence Bancorporation (CADE) - Class Action Alert- Bronstein, Gewirtz & Grossman, LLC |
09/23/2019 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MINDBODY, Inc. - MB |
09/20/2019 |
GN
| INVESTOR ALERT - MINDBODY, Inc. (MB) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: November 4, 2019 |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
Revenues | 182.6 | 139.0 | 101.4 | 70.0 | 48.7 | 32.0 |
Revenue growth | 31.4% | 37.1% | 44.8% | 43.8% | 52.2% | |
Cost of goods sold | 51.9 | 43.1 | 37.2 | 30.0 | 21.9 | 13.4 |
Gross profit | 130.8 | 95.9 | 64.2 | 40.0 | 26.8 | 18.6 |
Gross margin | 71.6% | 69.0% | 63.3% | 57.1% | 55.0% | 58.1% |
Sales and marketing | 71.8 | 56.5 | 46.3 | 30.9 | 21.0 | 11.7 |
Research and development | 35.8 | 30.3 | 23.1 | 16.2 | 10.5 | 3.7 |
General and administrative | 37.5 | 30.5 | 29.5 | 18.4 | 10.7 | 8.1 |
EBITA | -12.9 | -20.6 | -34.1 | -24.1 | -15.6 | -5.0 |
EBITA margin | -7.1% | -14.8% | -33.6% | -34.4% | -32.0% | -15.6% |
Amortization of intangibles | 1.4 | 0.7 | 0.7 | | 0.3 | |
EBIT | -14.4 | -21.3 | -34.7 | -24.1 | -15.8 | -5.0 |
EBIT margin | -7.9% | -15.3% | -34.3% | -34.4% | -32.5% | -15.6% |
Pre-tax income | -14.6 | -22.7 | -35.8 | -24.5 | -16.2 | -5.5 |
Income taxes | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.0 |
Net income | -14.8 | -23.0 | -44.2 | -45.9 | -44.1 | -18.5 |
Net margin | -8.1% | -16.5% | -43.6% | -65.6% | -90.7% | -58.0% |
|
Diluted EPS | ($0.33) | ($0.58) | ($1.68) | ($4.17) | ($4.10) | ($1.84) |
Shares outstanding (diluted) | 44.3 | 39.9 | 26.3 | 11.0 | 10.8 | 10.1 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|